44 results on '"Lee, V.H.F."'
Search Results
2. Differences Between the East and the West in Managing Advanced-Stage Non-small Cell Lung Cancer
3. EP08.02-25 A Case of Persistent Complete Response To Personalized Osimertinib and Concurrent Chemoradiation for Stage IIIC EGFRm NSCLC
4. 1279P First-line lorlatinib vs crizotinib in Asian patients with ALK+ non-small cell lung cancer (NSCLC): 5-year outcomes from the CROWN study
5. Integrative Palliative Cancer Care in Hong Kong: An Overview and an Example from the East
6. Advancing Care for Head and Neck Cancers in a Multidisciplinary Tumour Board in the East
7. Contrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West
8. Gastric Cancer – From Aetiology to Management: Differences Between the East and the West
9. The Role of Radiotherapy in Epidermal Growth Factor Receptor Mutation-positive Patients with Oligoprogression: A Matched-cohort Analysis
10. Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
11. Post-radiation Plasma Epstein-Barr Virus DNA and Local Clinical Remission After Radical Intensity-modulated Radiation Therapy for Nasopharyngeal Carcinoma
12. 247TiP Addition of induction, concurrent and maintenance durvalumab to induction and concurrent chemoradiation vs induction and concurrent chemoradiation for previously untreated locoregionally advanced nasopharyngeal carcinoma: A phase II randomised-controlled trial
13. 1111P Real-world treatment duration in patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (EGFRex20ins) mutations receiving mobocertinib through the global Expanded Access Program (EAP)
14. P4.17F.04 Feasibility of Comprehensive Genomic Profiling for Advanced NSCLC in Public Healthcare System - The Hong Kong Experience
15. 1884P Development and validation of a prediction tool for severe treatment-related toxicities in older cancer patients on systemic treatment (TR-TRM)
16. 1254MO Safety and anti-tumour activity of zipalertinib in NSCLC patients (pts) with EGFR exon 20 insertion (ex20ins) mutations who received prior amivantamab
17. 1238TiP Combining immunotherapy with Trop2 ADc in early stage non-small cell lung cancer (CITADEL)
18. PD-0154 Early prediction of therapeutic response by regular functional MRI during the treatment of NPC
19. HCC Etiology-Dependent Tumor Control Probability Model After Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: A Pooled Analysis of an Asian Liver Radiation Therapy Group Study
20. 858O Results of KEYNOTE-122: A phase III study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC)
21. 1197P First-line lorlatinib versus crizotinib in ALK-positive non-small cell lung cancer: Asian subgroup analysis of CROWN
22. PO-1684 Correlations of tumour permeability parameters from DCE-MRI with ADC in nasopharyngeal carcinoma
23. 380MO A phase II trial of atezolizumab, bevacizumab, pemetrexed and carboplatin combination for metastatic EGFR-mutated NSCLC after TKI failure
24. Incidence and Predictive Factors of Late Mortality in 1353 Five-year Survivors of Nasopharyngeal Cancer (NPC)
25. 269MO Comparison of three induction chemotherapy regimens with gemcitabine plus cisplatin, cisplatin plus fluorouracil, and cisplatin plus capecitabine for locoregionally advanced nasopharyngeal carcinoma: A pooled analysis of two prospective studies
26. LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions
27. 1397P High incidence of treatment-related adverse events after combination EGFR tyrosine-kinase inhibitor and immune checkpoint inhibitors in EGFR-mutated metastatic non-small cell lung cancer: A systematic review and meta-analysis
28. 943P The most optimal induction chemotherapy regimen for loco-regionally advanced nasopharyngeal carcinoma: A network meta-analysis
29. 913MO Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma in Hong Kong (2001-2010): A territory-wide study by HKNPCSG
30. 1850P Immune-related endocrine dysfunction in Chinese: A single tertiary centre experience
31. A pilot cross-sectional study on incidence of liver toxicity in cancer patients on western anti-cancer drug therapy with or without concurrent Chinese herbal medicine
32. Development and validation of M1 substages for previously untreated metastatic nasopharyngeal carcinoma
33. 441P - A pilot cross-sectional study on incidence of liver toxicity in cancer patients on western anti-cancer drug therapy with or without concurrent Chinese herbal medicine
34. 295P - Development and validation of M1 substages for previously untreated metastatic nasopharyngeal carcinoma
35. PD-L1 hotspot in tumor-infiltrating lymphocytes of radically treated esophageal squamous cell carcinoma: Pattern of recurrence and long-term clinical outcomes
36. Lymphopenia association with planning target volume and lung V5 and its effect on survival of esophageal cancer receiving neoadjuvant chemo-radiation with Dutch CROSS regime
37. 256P To compare the efficacy and safety of pazopanib and sunitinib in metastatic renal cell carcinoma (RCC) of Chinese population
38. P-270 Regorafenib for metastatic colorectal cancer in community setting: a multicenter retrospective analysis in Hong Kong
39. PD-006 - PD-L1 hotspot in tumor-infiltrating lymphocytes of radically treated esophageal squamous cell carcinoma: Pattern of recurrence and long-term clinical outcomes
40. P-064 - Lymphopenia association with planning target volume and lung V5 and its effect on survival of esophageal cancer receiving neoadjuvant chemo-radiation with Dutch CROSS regime
41. LBA11 Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis.
42. 555P Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong.
43. 528P Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study.
44. Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.